Francisco Abad Santos-rekin lankidetzan egindako argitalpenak (23)

2024

  1. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

    Experimental Dermatology, Vol. 33, Núm. 8

  2. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790

2023

  1. DNA Methylation Description of Hippocampus, Cortex, Amygdala, and Blood of Drug-Resistant Temporal Lobe Epilepsy

    Molecular Neurobiology, Vol. 60, Núm. 4, pp. 2070-2085

2022

  1. CNVs Associated with Different Clinical Phenotypes of Psoriasis and Anti-TNF-Induced Palmoplantar Pustulosis

    Journal of Personalized Medicine, Vol. 12, Núm. 9

  2. Pharmacogenetics of Donepezil and Memantine in Healthy Subjects

    Journal of Personalized Medicine, Vol. 12, Núm. 5

2021

  1. ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics

    Biomedicine and Pharmacotherapy, Vol. 142

  2. DNA copy number variation associated with anti-tumour necrosis factor drug response and paradoxical psoriasiform reactions in patients with moderate-to-severe psoriasis

    Acta Dermato-Venereologica

  3. Epigenetics in Non-tumor Immune-Mediated Skin Diseases

    Molecular Diagnosis and Therapy, Vol. 25, Núm. 2, pp. 137-161

  4. Growth arrest and DNA damage-inducible proteins (GADD45) in psoriasis

    Scientific Reports, Vol. 11, Núm. 1

  5. Methylation in psoriasis. Does sex matter?

    Journal of the European Academy of Dermatology and Venereology

2020

  1. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs

    Experimental Dermatology, Vol. 29, Núm. 12, pp. 1225-1232

  2. Pharmacogenetics update on biologic therapy in psoriasis

    Medicina (Lithuania), Vol. 56, Núm. 12, pp. 1-15

  3. Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis

    Journal of the European Academy of Dermatology and Venereology

2019

  1. Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis

    Journal of the European Academy of Dermatology and Venereology

2018

  1. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 122, Núm. 5, pp. 501-511

  2. Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis

    British Journal of Dermatology

  3. Histone modifications associated with biological drug response in moderate-to-severe psoriasis

    Experimental Dermatology, Vol. 27, Núm. 12, pp. 1361-1371

  4. How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?

    Pharmacogenomics, Vol. 19, Núm. 16, pp. 1285-1297

  5. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis

    American Journal of Clinical Dermatology, Vol. 19, Núm. 2, pp. 209-222

  6. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis

    Pharmacogenomics, Vol. 19, Núm. 1, pp. 7-16